Correction: J Exp Clin Cancer Res 42, 76 (2023)
https://doi.org/10.1186/s13046-023-02649-6
Following publication of the original article [1], an error was identified in Fig. 2, specifically:
Fig. 2b - CL/F (mL/hr) needs to be corrected in CL/F (L/hr)
Furthermore, two Supplementary Materials should also be uploaded. The added Supplementary Materials are:
Additional file 7: Supplementary Materials and Methods.
Additional file 8: NEO-201 protocol.
This modification does not affect the integrity of the results.
Fig. 2.
Clinical Pharmacokinetics of NEO-201 A. NEO-201 serum concentrations averaged for each dose level and plotted over time. B. Noncompartmental analysis of first dose of NEO-201 including the mean estimates for relevant PK parameters during dense PK sampling following the first dose given on C1D1. *Data presented as arithmetic means (%CV) due to low numbers in each group. 1 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 2 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 3 Four patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. 4 One patient had insufficient terminal data to accurately estimate a half-life, thus clearance and volume too. 5 Two patients had inaccurate estimates of C1D1 clearance and volume due to an overestimation of AUCinf. C. Individual NEO-201 serum concentration–time profiles of 1.0 mg/kg cohort. D-E. Individual NEO-201 serum concentration–time profiles of patients in 1.5 mg/kg cohort (D) and 2.0 mg/kg cohort (E). F-G. Differences in NEO-201 distribution volume by sex (F) and body size (G)
Electronic supplementary material
Below is the link to the electronic supplementary material.
Additional file 7: Supplementary Materials and Methods.
Footnotes
The online version of the original article can be found at 10.1186/s13046-023-02649-6.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Christopher B. Cole and Maria Pia Morelli contributed equally to this work.
Contributor Information
Massimo Fantini, Email: massimo.fantini@precision-biologics.com.
Christina M. Annunziata, Email: annunzic@mail.nih.gov
References
- 1.Cole CB, Morelli MP, Fantini M, et al. First-in-human phase 1 clinical trial of anti-core 1 O-glycans targeting monoclonal antibody NEO-201 in treatment-refractory solid tumors. J Exp Clin Cancer Res. 2023;42:76. doi: 10.1186/s13046-023-02649-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Additional file 7: Supplementary Materials and Methods.